Preclinical Alzheimer's Disease Clinical Trial
Official title:
Alzheimer's Plasma Extension
The APEX study is a multicenter, observational study designed to capture longitudinal follow-up of plasma biomarkers and cognitive and functional assessments on individuals who screen failed in the AHEAD study over approximately 4 years. Approximately 1000 participants will be enrolled across three groups: - Group A: Approximately 500 participants who are discordant on screening (plasma positive / Positron Emission Tomography (PET) negative), - Group B: Approximately 250 participants who are concordant on screening (plasma negative / PET negative), and - Group C: Approximately 250 participants selected from the individuals who previously screen failed prior to PET for the AHEAD study with oversampling of racial and ethnic populations underrepresented in Alzheimer's disease (AD) clinical trials. Primary Objectives: - Collect longitudinal cognitive and functional assessments and blood-based biomarker data - Evaluate, characterize, and compare the longitudinal cognitive and functional data between the three groups of participants - Compare longitudinal change across race and ethnicity, sex, and Apolipoprotein E (ApoE) status Exploratory Objectives: • Collect baseline amyloid PET on participants without prior amyloid PET data (Group C)
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06033066 -
Financial Incentives and Recruitment to the APT Webstudy
|
N/A | |
| Recruiting |
NCT04851496 -
Amyloid Prediction in Early Stage Alzheimer's Disease From Acoustic and Linguistic Patterns of Speech - PAST Extension
|
||
| Completed |
NCT04828122 -
Amyloid Prediction in Early Stage Alzheimer's Disease From Acoustic and Linguistic Patterns of Speech
|
||
| Terminated |
NCT04846426 -
Amyloid Prediction in Early Stage Alzheimer's Disease From Acoustic and Linguistic Patterns of Speech - FUTURE Extension
|
||
| Completed |
NCT02045056 -
Modulation of Micro-RNA Pathways by Gemfibrozil in Predementia Alzheimer Disease
|
Early Phase 1 | |
| Completed |
NCT03370744 -
Prediction of Cognitive Decline by Neuroimaging Techniques and the Application in Diagnosis and Treatment of Preclinical AD
|
||
| Completed |
NCT02963415 -
Concurrent Aerobic Exercise and Virtual Reality Cognitive Training
|
N/A | |
| Active, not recruiting |
NCT04004767 -
TRC-PAD Program: In-Clinic Trial-Ready Cohort
|
||
| Recruiting |
NCT04468659 -
AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid
|
Phase 3 | |
| Recruiting |
NCT04937959 -
Amyloid Prediction in Early Stage Alzheimer's Disease Through Speech Phenotyping - PAST Extension
|
||
| Completed |
NCT04928976 -
Amyloid Prediction in Early Stage Alzheimer's Disease Through Speech Phenotyping
|
||
| Terminated |
NCT04951284 -
Amyloid Prediction in Early Stage Alzheimer's Disease Through Speech Phenotyping - FUTURE Extension
|